Evidence map›Paper›PMID 41134733›Full record

Trial reportCerebrovascular diseases (Basel, Switzerland)2026

Association of Angiotensin Inhibitors with Improved Outcome after Acute Intracerebral Hemorrhage: Secondary Analysis of the INTERACT3 Trial.

Adrian R Parry-Jones, Xinwen Ren, Stuart M Allan, Xia Wang, Craig S Anderson, Paul R Kasher

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cerebrovascular diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adrian R Parry-JonesGeoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust and University of Manchester, Manchester, UK, adrian.parry-jones@manchester.ac.uk.
Xinwen RenThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Stuart M AllanGeoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust and University of Manchester, Manchester, UK.
Xia WangThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Craig S AndersonThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Paul R KasherGeoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust and University of Manchester, Manchester, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

<p>Introduction: Drug screening with a zebrafish model of acute intracerebral hemorrhage (ICH) identified a neuroprotective effect of angiotensin converting enzyme inhibitor (ACE-I) drugs. We identified an association of early ACE-I treatment and favorable 90-day functional outcome in participants of the second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial. We aimed to confirm a relation between angiotensin inhibitors and good outcome in the larger, third INTEnsive care bundle with blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT3) dataset.

methodsThis is a post hoc analysis of INTERACT3 in patients with ICH surviving to day 7. Associations of early ACE-I or angiotensin-II receptor blocker (ARB) treatment and neurological impairment (National Institutes of Health Stroke Scale [NIHSS] scores) at day 7 and functional recovery (modified Rankin Scale [mRS] scores) at 6 months were tested in multiple regression and ordinal regression models, respectively, with adjustment for confounding variables.

resultsOf 6,692 participants included in analyses, 2,525 (36.2%) received ACE-I/ARB treatment by day 7. Treatment with an ACE-I/ARB (vs. no ACE-I/ARB) was significantly and independently associated with lower NIHSS scores at day 7 (β-coefficient -1.17, 95% confidence interval [CI] -1.59 to -0.74; p < 0.001) and better mRS scores at 6 months (odds ratio 0.83, 95% CI 0.75-0.93; p = 0.0007).

conclusionEarly treatment with an angiotensin inhibitor is associated with improved outcome after ICH. Further research is needed to test for heterogeneity by ACE-I/ARB drug and treatment window to plan a clinical trial in ICH. </p>.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsBlood PressureCerebral HemorrhageNeuroprotective AgentsAcute DiseaseAgedDisability EvaluationFemaleHumansMaleRecovery of FunctionTime FactorsTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsNeuroprotective AgentsAngiotensin-converting enzyme inhibitorsAngiotensin receptor blockersINTERACT3 clinical trialIntracerebral hemorrhageNeuroprotection

Identifiers

PMID41134733
PMCPMC12707886

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.